Paxalisib - Pi3K inhibitor will be used for 63 patients.ie. (21...

Paxalisib - Pi3K inhibitor will be used for 63 patients.ie. (21 evaluable patients for breast), (21 for lung), and (21 for other).

This is exactly what we have been talking about the market is way bigger than GBM alone

trials in breast, lung and other - with a potential of 200,000 in the US alone - that’s an opportunity to benefit many more suffers way better than the 12,500 US GBM patients alone - some x17 the raw numbers of potential on GBM.

Wonderful news and massively value enhancing.